Isatuximab (Sarclisa; Sanofi), carfilzomib (Kyprolis; Onyx Pharmaceuticals), lenalidomide (Revlimid; Celgene Corporation), and dexamethasone induction yielded deep responses and high MRD-negativity rates in patients with newly diagnosed multiple myeloma (NDMM), according to data from the phase 3 MIDAS trial (NCT04934475). The data, published in Blood, also showed no emerging safety concerns and no disruptions in stem cell collection. 1,2